knowledge -WSS

knowledge

author：entertainment 2025-10-02 21:04:40 - browse：869

New Sanofi Genzyme president Bill Sibold is the first person without any ties to Henri Termeer (inset) to lead the company. Jonathan Wiggs/Globe staff

CAMBRIDGE, Mass. — When drug giant Sanofi restructured its global business two years ago, its Genzyme division got a new name, Sanofi Genzyme, explicitly tying it to the French parent company. It also got new responsibilities and a larger “specialty care” portfolio covering everything from enzyme replacement to cancer and multiple sclerosis drugs.

Last week, Sanofi Genzyme — still the largest Massachusetts biotech, with about 5,000 workers — also got a new president, Bill Sibold. He’s the first one without any ties to the old Genzyme, an independent company that pioneered the rare-disease business model and catalyzed the local life sciences boom before accepting Sanofi’s $20.1 billion takeover offer in 2011.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Steward Health Care expansion into Malta flopped

knowledge

WSS

Will the IRA bring competition to the biologics market?

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

Acelyrin, a rare IPO success, stumbles in its first big test

Yancopoulos of Regeneron works to expand Dupixent success

Mirador, a new biotech startup, launches with $400 million

Regeneron agrees to White House price limits on anti

leisure time

knowledge

hotspot

Medicare details structure of new drug price negotiation program

FDA panel endorses Alnylam’s heart drug — after picking it apart

Medical records are filled with copy

Texas board proposes rules on abortion law emergency exemption

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

FDA approves updated Covid vaccines

Continuity nursing helped my family in our darkest PICU moments

Diabetes management: Digital health tools fall short, study says

Jerome Adams on the need for new antivirals for Covid

Acelyrin, a rare IPO success, stumbles in its first big test

explore

Chinese researcher claims birth of first gene

Biotech investment managers search for lucrative opportunities

Testing GLP

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

Chinese researcher claims birth of first gene

Medicare Advantage insurers pressure Biden for bigger payments

focus

focus

knowledge

leisure time